A highly neutralizing human monoclonal antibody targeting a novel linear epitope on staphylococcal enterotoxin B
Authors:
Open Access
- 10 June 2024
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 20 (1) , 2360338
Abstract
Staphylococcal Enterotoxin B (SEB), produced by Staphylococcus aureus (S. aureus), is a powerful superantigen that induces severe immune disruption and toxic shock syndrome (TSS) upon binding to MHC-II and TCR. Despite its significant impact on the pathogenesis of S. aureus, there are currently no specific therapeutic interventions available to counteract the mechanism of action exerted by this toxin. In this study, we have identified a human monoclonal antibody, named Hm0487, that specifically targets SEB by single-cell sequencing using PBMCs isolated from volunteers enrolled in a phase I clinical trial of the five-antigen S. aureus vaccine. X-ray crystallography studies revealed that Hm0487 exhibits high affinity for a linear B cell epitope in SEB (SEB138-147), which is located distantly from the site involved in the formation of the MHC-SEB-TCR ternary complex. Furthermore, in vitro studies demonstrated that Hm0487 significantly impacts the interaction of SEB with both receptors and the binding to immune cells, probably due to an allosteric effect on SEB rather than competing with receptors for binding sites. Moreover, both in vitro and in vivo studies validated that Hm0487 displayed efficient neutralizing efficacy in models of lethal shock and sepsis induced by either SEB or bacterial challenge. Our findings unveil an alternative mechanism for neutralizing the pathogenesis of SEB by Hm0487, and this antibody provides a novel strategy for mitigating both SEB-induced toxicity and S. aureus infection.Keywords
Funding Information
- National Key Research and Development Program of China (2021YFC2301405)
- National Natural Science Foundation of China (32070941, 32270989)
This publication has 41 references indexed in Scilit:
- Immune evasion by staphylococciNature Reviews Microbiology, 2005
- Vaccines against the category B toxins: Staphylococcal enterotoxin B, epsilon toxin and ricinAdvanced Drug Delivery Reviews, 2005
- Differences in Potency of Intravenous Polyspecific Immunoglobulin G against Streptococcal and Staphylococcal Superantigens: Implications for Therapy of Toxic Shock SyndromeClinical Infectious Diseases, 2004
- Identification of critical residues of staphylococcal enterotoxin B for lymphomonocyte proliferation and cytokine productionChemical Biology & Drug Design, 1998
- Molecular characterization of the putative T‐cell receptor cavity of the superantigen staphylococcal enterotoxin BImmunology, 1998
- A Mutational Analysis of the Binding of Staphylococcal Enterotoxins B and C3 to the T Cell Receptor β Chain and Major Histocompatibility Complex Class IIJournal of Experimental Medicine, 1998
- Intercellular Adhesion Molecule-1 and Leukocyte Function-Associated Antigen-3 Provide Costimulation for Superantigen-Induced T Lymphocyte Proliferation in the Absence of a Specific Presenting MoleculeThe Journal of Immunology, 1998
- Multiple Binding-Sites on the Superantigen, Staphylococcal Enterotoxin B, Imparts Versatility in Binding to MHC Class II MoleculesBiochemical and Biophysical Research Communications, 1994
- Crystal structure of staphylococcal enterotoxin B, a superantigenNature, 1992
- T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor.Journal of Experimental Medicine, 1992